■蛋白酪氨酸磷酸酶(PTP),必需的和进化上高度保守的酶,通过调节酪氨酸磷酸化来管理细胞功能,信号转导的关键翻译后修饰。磷酸酶药物发现的最新进展,导致酶的选择性调节剂的鉴定,恢复对蛋白质磷酸酶治疗靶向的兴趣。
■截至2023年的专利汇编侧重于各种类别的酪氨酸磷酸酶及其抑制剂的功效,详细说明它们的化学结构和生化特性。这些发现具有广泛的含义,因为它们可以用于治疗癌症等多种疾病,糖尿病,自身免疫性疾病,和神经系统疾病。科学文章和专利文献的搜索是使用众所周知的不同平台进行的,以收集截至2023年的信息。
■蛋白酪氨酸磷酸酶(PTP)研究的最新进展包括发现了靶向特定PTP酶的新抑制剂,重点开发变构位点共价抑制剂,以增强疗效和特异性。这些进步不仅为各种疾病的治疗干预开辟了新的可能性,而且还具有创新治疗的潜力。PTP为一系列健康状况的药物发现工作和创新治疗提供了有希望的途径。
UNASSIGNED: Protein tyrosine phosphatases (PTPs), essential and evolutionarily highly conserved enzymes, govern cellular functions by modulating tyrosine phosphorylation, a pivotal post-translational modification for signal transduction. The recent strides in phosphatase drug discovery, leading to the identification of selective modulators for enzymes, restoring interest in the therapeutic targeting of protein phosphatases.
UNASSIGNED: The compilation of patents up to the year 2023 focuses on the efficacy of various classes of Tyrosine phosphatases and their inhibitors, detailing their chemical structure and biochemical characteristics. These findings have broad implications, as they can be applied to treating diverse conditions like cancer, diabetes, autoimmune disorders, and neurological diseases. The search for scientific articles and patent literature was conducted using well known different platforms to gather information up to 2023.
UNASSIGNED: The latest improvements in protein tyrosine phosphatase (PTP) research include the discovery of new inhibitors targeting specific PTP enzymes, with a focus on developing allosteric site covalent inhibitors for enhanced efficacy and specificity. These advancements have not only opened up new possibilities for therapeutic interventions in various disease conditions but also hold the potential for innovative treatments. PTPs offer promising avenues for drug discovery efforts and innovative treatments across a spectrum of health conditions.